Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroectodermal Tumors × Lomustine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 45 Brain Neoplasms 24 Central Nervous System Neoplasms 21 Astrocytoma 16 Glioma 15 Medulloblastoma 9 Oligodendroglioma 7 Neoplasms 7 Lymphoma 7 Recurrence 6 Gliosarcoma 6 Spinal Cord Neoplasms 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Lymphoma, AIDS-Related 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Ependymoma 2 Burkitt Lymphoma 2 Uveal Melanoma 1 Solid Tumor 1 Sarcoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Optic Nerve Glioma 1 Neuroectodermal Tumors, Primitive 1 Neuroectodermal Tumors 1 Neoplasms, Plasma Cell 1

Interventions

Vincristine 2 Temozolomide 2 vorasidenib 1 repotrectinib 1 pralsetinib 1 pembrolizumab 1 pamiparib 1 lutetium Lu 177 dotatate 1 copper dotatate CU-64 1 cixutumumab 1 Vorinostat 1 Valproic Acid 1 Thiotepa 1 Sunitinib 1 Radiotherapy 1 Radiation 1 Peripheral Blood Stem Cell Transplantation 1 Oncolytic Virotherapy 1 ONC206 1 Melphalan 1 Maintenance Chemotherapy 1 Lutetium-177 1 Lutetium 1 Lomustine 1 Interleukin-12 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Etoposide 1 Erlotinib Hydrochloride 1 Doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01614132 2020-03-31

NOA-07

University of Regensburg

Phase 1/2 Completed

Medulloblastoma, Neoplasms, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡